Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Export

@article{citeulike:3399250, abstract = {Epidemiologic studies fairly consistently show in postmenopausal women that reproductive steroid hormones contribute to primary breast cancer risk, and this association is strongly supported by experimental studies using laboratory animals and model systems. Evidence linking sex hormone concentrations with risk for recurrence in women diagnosed with breast cancer is limited; however, beneficial effects of antiestrogenic therapy on recurrence-free survival suggest that these hormones affect progression and risk for recurrence. This study examined whether baseline serum concentrations of estradiol, testosterone, and sex hormone binding globulin were associated with recurrence-free survival in a nested case-control cohort of women from a randomized diet trial (Women's Healthy Eating and Living Study) who were followed for >7 years after diagnosis. In 153 case-control pairs of perimenopausal and postmenopausal women in this analysis, total estradiol [hazard ratio (HR), 1.41 per unit increase in log concentration; 95\% confidence interval (95\% CI), 1.01-1.97], bioavailable estradiol (HR, 1.26; 95\% CI, 1.03-1.53), and free estradiol (HR, 1.31; 95\% CI, 1.03-1.65) concentrations were significantly associated with risk for recurrence. Recurred women had an average total estradiol concentration that was double that of nonrecurred women (22.7 versus 10.8 pg/mL; P = 0.05). Testosterone and sex hormone binding globulin concentrations did not differ between cases and controls and were not associated with risk for recurrence. Although genetic and metabolic factors likely modulate the relationship between circulating sex hormones and risk, results from this study provide evidence that higher serum estrogen concentration contributes to risk for recurrence in women diagnosed with early stage breast cancer.}, author = {Rock, C. L. and Flatt, S. W. and Laughlin, G. A. and Gold, E. B. and Thomson, C. A. and Natarajan, L. and Jones, L. A. and Caan, B. J. and Stefanick, M. L. and Hajek, R. A. and Al-Delaimy, W. K. and Stanczyk, F. Z. and Pierce, J. P. and {}}, citeulike-article-id = {3399250}, citeulike-linkout-0 = {http://dx.doi.org/10.1158/1055-9965.EPI-07-0761}, citeulike-linkout-1 = {http://cebp.aacrjournals.org/cgi/content/abstract/17/3/614}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/18323413}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=18323413}, day = {1}, doi = {10.1158/1055-9965.EPI-07-0761}, issn = {1055-9965}, journal = {Cancer epidemiology, biomarkers \& prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology}, keywords = {superlist, thelist}, month = {March}, number = {3}, pages = {614--620}, posted-at = {2009-07-18 22:34:22}, priority = {2}, title = {Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer.}, url = {http://dx.doi.org/10.1158/1055-9965.EPI-07-0761}, volume = {17}, year = {2008} }

TY - JOUR ID - citeulike:3399250 L3 - citeulike-article-id:3399250 N2 - Epidemiologic studies fairly consistently show in postmenopausal women that reproductive steroid hormones contribute to primary breast cancer risk, and this association is strongly supported by experimental studies using laboratory animals and model systems. Evidence linking sex hormone concentrations with risk for recurrence in women diagnosed with breast cancer is limited; however, beneficial effects of antiestrogenic therapy on recurrence-free survival suggest that these hormones affect progression and risk for recurrence. This study examined whether baseline serum concentrations of estradiol, testosterone, and sex hormone binding globulin were associated with recurrence-free survival in a nested case-control cohort of women from a randomized diet trial (Women's Healthy Eating and Living Study) who were followed for >7 years after diagnosis. In 153 case-control pairs of perimenopausal and postmenopausal women in this analysis, total estradiol [hazard ratio (HR), 1.41 per unit increase in log concentration; 95% confidence interval (95% CI), 1.01-1.97], bioavailable estradiol (HR, 1.26; 95% CI, 1.03-1.53), and free estradiol (HR, 1.31; 95% CI, 1.03-1.65) concentrations were significantly associated with risk for recurrence. Recurred women had an average total estradiol concentration that was double that of nonrecurred women (22.7 versus 10.8 pg/mL; P = 0.05). Testosterone and sex hormone binding globulin concentrations did not differ between cases and controls and were not associated with risk for recurrence. Although genetic and metabolic factors likely modulate the relationship between circulating sex hormones and risk, results from this study provide evidence that higher serum estrogen concentration contributes to risk for recurrence in women diagnosed with early stage breast cancer. IS - 3 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology SN - 1055-9965 EP - 620 TI - Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. VL - 17 SP - 614 KW - superlist KW - thelist AU - Rock, CL AU - Flatt, SW AU - Laughlin, GA AU - Gold, EB AU - Thomson, CA AU - Natarajan, L AU - Jones, LA AU - Caan, BJ AU - Stefanick, ML AU - Hajek, RA AU - Al-Delaimy, WK AU - Stanczyk, FZ AU - Pierce, JP PY - 2008/03/01/ UR - http://dx.doi.org/10.1158/1055-9965.EPI-07-0761 ER -